Gregory S. Hageman

Document Sample
Gregory S. Hageman Powered By Docstoc
					                              Gregory S. Hageman

       Gregory S. Hageman, Ph.D., is a Professor of Ophthalmology and Visual
Sciences at the University of Iowa Carver College of Medicine, where he directs
the Cell Biology and Functional Genomics Laboratory. He holds additional
appointments as a Senior Member of the University of Iowa Center for Macular
Degeneration, an Associate Faculty in the Center for the Study of Macular
Degeneration, University of California, Santa Barbara, and Honorary
Professorships at Queen’s University, Belfast, UK and Shandong Eye Institute,
Qingdao, China. Dr. Hageman is a graduate of the University of Southern
California, where he conducted both his undergraduate and graduate studies in
biology and marine biology. He has been at the University of Iowa since 1997.
       Dr. Hageman is an active member of various professional and honorary
organizations including the Macula Society, and has served on a number of
national and international advisory boards, service panels and review
committees, including NIH ASG, VSN, BDPE and VISC study sections, the
Foundation Fighting Blindness, the International Society for Ocular Cell Biology
and the Deutsche Forschungsgemeinschaft Priority Program in Age-related
Macular Degeneration. He also serves or has served as an advisor to
Genentech, Alcon, Pfizer, OccuLogix, Novartis, Tanox and American Home
Products.
       Dr. Hageman is an author or co-author on approximately 100 refereed or
invited publications, as well as numerous issued patents and pending patent
applications. His primary research interests over the past 16 years have been
directed toward assessment of pathways involved in the aetiology of age-related
macular degeneration (AMD), the leading cause of irreversible worldwide
blindness. Dr. Hageman has garnered contiguous funding over the past 22
years from the National Eye Institute/National Institutes of Health, in addition to
that from numerous foundations and pharmaceutical companies. He is the
principal investigator of a recently awarded $14.6M R24 translational award
supported by NIH/NEI and involving 12 participating institutions. Dr. Hageman
and his colleagues have shown recently that a specific common haplotype of the
complement regulator, Factor H (CFH), in combination with variations in another
complement regulator, Factor B (CFB), account for approximately 75% of AMD in
the human population. He was recently invited to present his research findings
to Congress. He received the Trustee Award from Foundation Fighting
Blindness, the Roger Johnson Prize for Macular Degeneration and has
presented a number of named lectureships for these studies.
       Dr. Hageman is a founder in a new company that has partnered with the
University of Iowa and various commercial entities; this company will serve as a
platform for the development of diagnostics and therapeutics for the treatment of
AMD.